Story at a glance
- Experts are still learning about immune responses to the novel coronavirus and the vaccines.
- A small study finds evidence that suggests that people who have recovered benefit from one dose of Pfizer/BioNTech or Moderna vaccines but may not receive additional benefit from a second dose.
- The researchers are conducting large scale studies to further investigate this.
A team of researchers at the Penn Institute of Immunology took blood samples from 44 study participants before and while they were receiving either the Pfizer/BioNTech or Moderna vaccines. Of the participants, 33 were naive to the SARS-CoV-2 coronavirus and 11 were recovered from previous SARS-CoV-2 infection.
The researchers took blood samples four times: baseline, 2 weeks post-primary immunization, day of booster immunization, and 1 week post-booster immunization, according to the paper published in Science Immunology. In their analysis, they focused on looking for memory B cells, which are important for long-term immunity. “Memory B cells are a strong predictor of future antibody responses, which is why it’s vital to measure B cell responses to these vaccines,” says E. John Wherry in a press release. “This effort to examine memory B cells is important for understanding long-term protection and the ability to respond to variants.”
Our country is in a historic fight against the Coronavirus. Add Changing America to your Facebook or Twitter feed to stay on top of the news.
They also tested for antibodies, which for recovered participants they did not see an increase after the second vaccine dose. SARS-CoV-2 antigen-specific B cells were minimal in naive individuals but were present in recovered people. The researchers also saw that B cells were significantly boosted in naive people after the second vaccine dose while recovered people had a “robust expansion” after the first dose. They write in the paper, “a single dose of mRNA vaccine amplified pre-existing antigen-specific memory B cells in SARS-CoV-2 recovered subjects, with no additional quantitative benefit after the second vaccine dose.”
However, these results are for a very small sample size of only 11 people who recovered from the coronavirus. The researchers are continuing with larger scale studies to examine further if COVID-19 recovered individuals should get a one or two dose regimen and to see how long the antibodies last, according to the press release.
WHAT YOU NEED TO KNOW ABOUT CORONAVIRUS RIGHT NOW
CDC GIVES NEW MASK GUIDANCE FOR OUTDOORS AND INDOORS
CDC INVESTIGATING NEW REPORTS OF BLOOD CLOT CASES LINKED TO J&J VACCINE
PFIZER-BIONTECH BOOSTER LIKELY NEEDED AS IMMUNITY WANES, SAYS SCIENTIST WHO HELPED DEVELOP VACCINE
AFTER CALLING IT A SCAM, CONTROVERSIAL ROCKER TED NUGENT CONTRACTS COVID-19
Published on Apr 29,2021